Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chorionic gonadotropin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    681 result(s) found for: Chorionic gonadotropin. Displaying page 5 of 35.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-000618-35 Sponsor Protocol Number: M07PGC Start Date*: 2007-11-29
    Sponsor Name:Rigshospitalet
    Full Title: PHASE II TRIAL OF PACLITAXEL, GEMCITABINE AND CISPLATIN IN PATIENTS WITH RELAPSING GERM CELL CANCER AFTER FIRST LINE CHEMOTHERAPY
    Medical condition: · The primary objective of this study is to investigate the combination of cisplatin/gemcitabine/paclitaxel, with respect to progression free survival in patients with germ cell tumours previously...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing) DK (Completed) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003702-26 Sponsor Protocol Number: E2007-G000-208 Start Date*: 2007-01-10
    Sponsor Name:Eisai Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Explore the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients with Refractory Partial Seizures
    Medical condition: Refractory Partial Seizures
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061334 Partial seizures LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) LV (Completed) EE (Completed) LT (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-001247-39 Sponsor Protocol Number: CCR104456 Start Date*: 2005-08-16
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing opti...
    Medical condition: Treatment of HIV-1 infections
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) IE (Completed) DK (Prematurely Ended) GB (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000914-19 Sponsor Protocol Number: EPO-ANE-4008 Start Date*: 2006-10-23
    Sponsor Name:Janssen-Cilag International N.V., Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A randomized, open-label, multicenter study evaluating thrombovascular events in subjects with cancer receiving chemotherapy and administered epoetin alfa once or three times a week for the treatme...
    Medical condition: Anemia in cancer patients receiving chemotherapy MedDRA Version 5.1 : list of preferred terma used in the process of defining thrombotic vascular events, see investigators brochure epoetin alpha.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) SK (Completed) GR (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005936-29 Sponsor Protocol Number: 0881A6-318-EU Start Date*: 2006-09-28
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical research and Development [...]
    1. Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical research and Development
    2. Wyeth Pharmaceuticals France, Wyeth Research Division
    Full Title: A Multicenter, Parallel, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Moderate to Severe Plaque Psoriasis
    Medical condition: moderate to severe plaque psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) ES (Completed) NL (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000753-80 Sponsor Protocol Number: 000298 Start Date*: 2022-08-04
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A randomised, assessor-blind, active-controlled, parallel-group, dose-finding trial to investigate the efficacy and safety of FE 999302 for triggering of final follicular maturation in women underg...
    Medical condition: Infertility
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004872 10016398 Female infertility LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended) CZ (Prematurely Ended) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-002612-52 Sponsor Protocol Number: LUCAS Start Date*: 2021-02-19
    Sponsor Name:Department of Endocrinology, Rigshospitalet
    Full Title: A randomized, double-blinded, clinical, placebo-controlled trial on the effects of therapy with Letrozole and hUman Choriongonadotropin in male hypogonadism induced by illicit use of Anabolic andro...
    Medical condition: Male hypogonadism related to illicit use of anabolic androgenic steroids
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10058359 Hypogonadism PT
    21.0 10038604 - Reproductive system and breast disorders 10021926 Infertility PT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011135-13 Sponsor Protocol Number: BIA-2093-311 Start Date*: 2010-06-29
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS MONOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED PARTIAL-ONSET SEIZURES: A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, MU...
    Medical condition: Adult patients with newly diagnosed partial-onset seizures
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10065336 Partial epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) AT (Completed) FI (Completed) LT (Completed) PT (Completed) GB (Completed) SK (Completed) ES (Completed) IT (Completed) CZ (Completed) LV (Completed) BE (Completed) EE (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-001721-13 Sponsor Protocol Number: TAK-013/EC-302 Start Date*: 2005-01-24
    Sponsor Name:Takeda Europe R&D Center Ltd
    Full Title: A Phase III, multi-center, randomized, double-blind study to evaluate the efficacy and safety of 50 mg and 100 mg of sufugolix (TAK-013) tablets administered twice daily versus placebo for 12 weeks...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    7 10014778 LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2004-001720-21 Sponsor Protocol Number: TAK-013/EC301 Start Date*: 2004-12-24
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A Phase III, multi-center, randomized, double-blind comparator study to evaluate the efficacy and safety of 50 mg and 100 mg of TAK-013 tablets administered twice daily versus 3.75mg of Leuprolide ...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    7 10014778 LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-002992-33 Sponsor Protocol Number: 54135419TRD3013 Start Date*: 2020-08-04
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared Wit...
    Medical condition: Treatment-Resistant Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed) PL (Completed) DE (Completed) HU (Completed) FR (Completed) BE (Completed) PT (Completed) BG (Completed) DK (Completed) AT (Completed) NO (Completed) FI (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003987-29 Sponsor Protocol Number: APD334-303 Start Date*: 2019-06-25
    Sponsor Name:Arena Pharmaceuticals Inc. a wholly owned subsidiary of Pfizer Inc.
    Full Title: An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    20.1 10017947 - Gastrointestinal disorders 10045366 Ulcerative colitis, unspecified LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) BE (Trial now transitioned) NL (Ongoing) CZ (Trial now transitioned) EE (Ongoing) FR (Trial now transitioned) LV (Completed) HU (Trial now transitioned) DE (Trial now transitioned) DK (Completed) AT (Completed) BG (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) HR (Completed) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005098-28 Sponsor Protocol Number: GTI1305 Start Date*: 2015-01-16
    Sponsor Name:Grifols Therapeutics LLC.
    Full Title: A multicenter, prospective, open-label, non-controlled clinical trial to assess the efficacy and safety of Immune Globuline (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in patients with ...
    Medical condition: Myasthenia Gravis Exacerbations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) BE (Completed) RO (Completed) PL (Completed) EE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2012-004492-38 Sponsor Protocol Number: PUMA-NER-1301 Start Date*: 2013-07-30
    Sponsor Name:Puma Biotechnology, Inc.
    Full Title: A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastati...
    Medical condition: HER2+ Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FI (Completed) IT (Completed) BE (Completed) CZ (Completed) ES (Completed) AT (Completed) SE (Completed) IE (Completed) DK (Prematurely Ended) PT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004726-34 Sponsor Protocol Number: SHP620-302 Start Date*: 2017-09-01
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegaloviru...
    Medical condition: Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021819 Infection in marrow transplant recipients LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) CZ (Completed) PL (Completed) FR (Completed) HR (Completed) IT (Completed) GR (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000413-20 Sponsor Protocol Number: 3000-03-005/ENGOT-OV44/GSK213350 Start Date*: 2018-11-07
    Sponsor Name:TESARO, Inc.
    Full Title: A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Non-muc...
    Medical condition: Stage 3 or 4 High Grade Non-mucinous epithelial ovarian cancer (serous, endometrial, clear cell, carcinosarcoma, and mixed pathologies)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) NL (Ongoing) ES (Ongoing) NO (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002817-21 Sponsor Protocol Number: AC-065A310 Start Date*: Information not available in EudraCT
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as ...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) SE (Trial now transitioned) DE (Ongoing) ES (Ongoing) HU (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004896-20 Sponsor Protocol Number: SPD476-314 Start Date*: 2008-05-20
    Sponsor Name:Shire Pharmaceutical Development Limited
    Full Title: A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence...
    Medical condition: Treatment of Diverticulitis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10013538 Diverticulitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DE (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-000064-28 Sponsor Protocol Number: RAP-MD-33 Start Date*: 2018-11-28
    Sponsor Name:Allergan Ltd.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel in the Prevention of Relapse in Patients with Major Depressive Disorder
    Medical condition: Major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SE (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002619-89 Sponsor Protocol Number: B1761031 Start Date*: 2019-06-05
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG™) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTOR...
    Medical condition: relapsed or refractory CD33-positive acute myeloid leukaemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 03:25:32 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA